Inspire Medical Systems delivered a robust second quarter, with revenue growth of 30% year-over-year and a significant improvement in profitability, leading to raised full-year guidance.
Summary
Inspire Medical Systems reported Q2 2024 revenue of $195.9 million, representing a 30% increase compared to the same period last year. The company achieved net income of $9.8 million, a substantial improvement from a net loss of $12 million in Q2 2023. CEO Tim Herbert emphasized the company’s commitment to patient outcomes:
“We always start our earnings call by reiterating our commitment to delivering strong and consistent patient outcomes. Our mission is to put the patient first, and we now have over 75,000 patients treated with Inspire therapy to date.”
Main Themes
- Guidance: Full-year 2024 revenue guidance increased to $788-798 million (26-28% growth)
- New Product Announcements: FDA approval for Inspire V neurostimulation system
- Market-moving information: Diluted net income guidance raised to $0.60-$0.80 per share for 2024
- Economic outlook: Strong patient demand and improved reimbursement landscape
- Competition: Complementary impact of GLP-1 drugs on Inspire therapy market opportunity
Insights
Inspire Medical Systems is leveraging advanced practice providers (APPs) to improve capacity in both sleep and ENT clinics, addressing strong patient demand. The company has hosted over 150 APPs in training programs year-to-date. Additionally, Inspire is expanding its presence in primary care and cardiology conferences to drive increased awareness of its therapy.
Market Opportunity
The company sees a significant opportunity in patients using GLP-1 drugs for weight loss. As these patients lose weight, they may become better candidates for Inspire therapy due to reduced lateral wall collapse. Third-party data shows over 1,500 patients in the past two years received Inspire therapy while actively on GLP-1 therapy, indicating a complementary relationship between the treatments.
Market Commentary
Inspire Medical Systems received EU MDR certification in Europe, including full-body MRI compatibility. This certification allows the company to submit new products for approval in the European market. Additionally, the company obtained countrywide reimbursement in France, the second-largest obstructive sleep apnea (OSA) market in Europe, at levels consistent with other European countries.
Customer Behaviors
The company is seeing increased adoption of digital tools to improve the patient experience. Over 200 centers are now using digital scheduling to book appointments, resulting in a 60% increase in patients’ ability to schedule appointments on their first attempt.
Regulatory Policy
Inspire Medical Systems is making progress with the PREDICTOR study, which aims to eliminate the need for drug-induced sleep endoscopy (DICE) in patients with lower BMI. Several payers have already updated their policies to remove the DICE requirement based on discussions about the study results.
Economy Insights
The proposed 2025 National Medicare outpatient payment rates call for a 2% increase for hospital outpatient procedures and a 3% increase for ambulatory surgical centers. This positive reimbursement trend supports continued growth in Inspire therapy adoption.
Industry Insights
The success of GLP-1 drugs in weight loss may expand the addressable market for Inspire therapy. As patients lose weight, they may become better candidates for the treatment, potentially increasing demand for hypoglossal nerve stimulation devices across the industry.
Key Metrics
Financial Metrics:
- Q2 2024 Revenue: $195.9 million (30% YoY growth)
- U.S. Revenue: $187.8 million (30% YoY growth)
- International Revenue: $8.1 million (27% YoY growth)
- Net Income: $9.8 million (vs. $12 million net loss in Q2 2023)
- Gross Margin: 84.8% (up from 83.9% in Q2 2023)
KPIs:
- Active U.S. Centers: 1,316
- U.S. Sales Territories: 310
- New U.S. Implanting Centers in Q2: 81
- New U.S. Sales Territories in Q2: 12
- Patients Treated with Inspire Therapy: Over 75,000
“We now have 1,316 active U.S. centers and 310 sales territories.”
Competitive Differentiators
- Proprietary Inspire V neurostimulation system with integrated respiratory sensing capabilities
- Strong patient outcomes and growing clinical evidence base
- Expanding reimbursement coverage and improving market access
- Complementary relationship with GLP-1 weight loss drugs
- Digital tools improving patient experience and clinic efficiency
Key Risks
- Potential disruption during transition to Inspire V system
- Dependence on reimbursement policies and payer decisions
- Competition from alternative sleep apnea treatments
- Regulatory challenges in international markets
- Execution risks associated with rapid growth and expansion
Analyst Q&A Focus Areas
Analysts focused on:
- Sustainability of Q2 performance and future growth trajectory
- Inspire V rollout strategy and potential impact on procedure volumes
- Utilization trends and capacity expansion initiatives
- Impact of GLP-1 drugs on the addressable market
- Operating leverage and profitability outlook
Inspire Medical Systems Summary:
Inspire Medical Systems delivered strong Q2 results, demonstrating robust revenue growth and a significant improvement in profitability. The company’s focus on expanding its therapy adoption through increased market penetration, new product innovations, and improved patient experience positions it well for continued growth. Key areas to watch include the rollout of the Inspire V system, the impact of GLP-1 drugs on the addressable market, and the company’s ability to maintain strong growth while improving profitability.
